Jpmorgan Chase & CO Seres Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,304 shares of MCRB stock, worth $20,133. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,304
Previous 1,304
-0.0%
Holding current value
$20,133
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MCRB
# of Institutions
9Shares Held
1.98MCall Options Held
10KPut Options Held
0-
Black Rock Inc. New York, NY1.76MShares$27.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY150KShares$2.31 Million0.0% of portfolio
-
Kestra Advisory Services, LLC38.5KShares$593,9920.0% of portfolio
-
Miller Financial Services LLC Marshall, MI15KShares$231,6000.02% of portfolio
-
Pictet Asset Management Sa Geneva 73, V813.7KShares$211,4040.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $1.92B
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...